Sign in
Taking people in United StatesNo phase

Follows adults with acute pancreatitis to see if diabetes develops

Observes adults aged 18 to 75 after acute pancreatitis over 36 months.

Key facts

Who runs it
Milton S. Hershey Medical Center
Where
Baltimore, Chicago, Columbus, Gainesville, Indianapolis, Los Angeles, Minneapolis, Orlando, Pittsburgh, Seattle, and Stanford, United StatesSee the 13 sites
Trial code
Registry title
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
Status
Recruiting
People taking part
800 people, planned
Started
14 Jan 2022
Expected to end
31 Jan 2030
Type of study
Observational
Record updated
18 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who were diagnosed with acute pancreatitis in the last 90 days. It follows them for 36 months to study diabetes that can come after acute pancreatitis.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
Acute pancreatitis diagnosed 0-90 days before joining the study.
Earlier treatment
People who already had direct endoscopic necrosectomy, percutaneous necrosectomy or drainage of necrotic collections, or pancreatic surgery cannot join. Certain medicines are not allowed in the 30 days before joining.

Main reasons for not taking part

  • Definite chronic pancreatitis shown on CT, MRI or MRCP
  • Pancreatic tumors, or a cystic tumor linked to the cause of the pancreatitis
  • Solid organ transplant, AIDS, cirrhosis, kidney disease with eGFR < 30 or dialysis before the pancreatitis, or cancer treatment in the last 12 months
  • Known pregnancy at the time of joining
  • Incarceration

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date
  • Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups

Who cannot take part

  • Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study
  • Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure
  • Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures
  • Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study
  • Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) < 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of <12 months
  • Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP
  • Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for <48 hours
  • Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis
  • Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)
  • Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety
  • Incarceration

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Johns Hopkins UniversityBaltimore, United StatesContact: Mahya FaghihTaking people
  • Northwestern UniversityChicago, United StatesContact: Christine NelsonTaking people
  • University of Illinois at ChicagoChicago, United StatesContact: Haya Al RashdanTaking people
  • Ohio State UniversityColumbus, United StatesContact: Zoe KrebsTaking people
  • University of FloridaGainesville, United StatesContact: Amber BoutonTaking people
  • Indiana UniversityIndianapolis, United StatesContact: Maureen Mullen-MontaganoTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Eleanor ChangTaking people
  • University of Southern CaliforniaLos Angeles, United StatesContact: Jessica SernaTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Heather HodgkinsTaking people
  • AdventHealthOrlando, United StatesContact: Gina MercoufferTaking people
  • University of PittsburghPittsburgh, United StatesContact: Shari ReynoldsTaking people
  • Benaroya Research InstituteSeattle, United StatesContact: Kim VarnerTaking people
  • Stanford UniversityStanford, United StatesContact: Lorena PinedaTaking people

About the trial

What the trial wants to find out

The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Diabetes RElated to Acute Pancreatitis and Its Mechanisms (DREAM) An Observational Cohort Study From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
Plain-language title
Follows adults with acute pancreatitis to see if diabetes developsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05197920, who can take part
Record updated
18 November 2025